SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection until 2044 for treating bipolar I disorder and schizophrenia. The community is actively debating the stock's significant undervaluation given this second recent approval, speculating on a potential buyout by larger pharmaceutical companies.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following recent exceptional Phase 2 clinical trial results for its lead drug in axial spondyloarthritis, demonstrating strong efficacy and potential disease-modifying effects. The community is highly bullish, anticipating further positive updates at an upcoming investor day and widely discussing the stock's significant undervaluation amid perceptions of market manipulation.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike faces a sharp sell-off across the cybersecurity sector, driven by market fears that Anthropic's new AI code security tool will disrupt traditional offerings. The community is fiercely debating whether this is an irrational overreaction, with many highlighting CRWD's distinct endpoint and cloud security services and arguing that AI-driven threats will actually increase demand for established cybersecurity leaders.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as reports surface of unsolicited takeover interest from rivals, some eyeing the entire company while others target specific assets like Venmo or Braintree following its significant stock slump. The community is actively debating potential buyers and buyout prices, largely driven by the belief that the fintech giant is fundamentally undervalued given its substantial free cash flow and ongoing share buyback program.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF ($IGV) is experiencing a significant sell-off and hitting new lows, fueled by widespread community fear that Anthropic's Claude AI tools will disrupt and replace traditional software. This "SaaS-pocalypse" is sparking intense debate among investors over whether the market's aggressive reaction is an overblown narrative or a fundamental threat.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is trending as the software sector faces a steep sell-off driven by fears that AI could disrupt its core business, despite counter-arguments that AI will enhance its established platforms. With earnings approaching, the community is fiercely divided between those who view the decline as an oversold buying opportunity and those who believe the AI threat justifies further downside.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

The community is fiercely debating Avalanche's substantial price drop to multi-year lows, driven by upcoming token unlocks and the disappointing lack of initial inflows for its recently launched ETF. This deep bearish sentiment persists despite its strong underlying fundamentals and institutional traction in real-world asset tokenization, exacerbated by broader crypto market volatility and regulatory uncertainty.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

Zscaler is facing intense selling pressure, hitting new lows, as the cybersecurity sector grapples with fears that AI tools like Anthropic's Claude Code Security could disrupt existing solutions, prompting community debate between panic selling and 'buy the dip' opportunities ahead of its earnings report.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is surging after Novo Nordisk's weight-loss drug CagriSema underperformed Eli Lilly's tirzepatide, intensifying speculation that Viking's VK2735, a dual GLP-1/GIP agonist with strong tolerability, is now an even more critical acquisition target for major pharma amid a significant short interest.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is trending due to its proactive integration of AI in payments and robust earnings report, while the community actively debates both the disruptive potential of AI in financial services and the indirect market impact of proposed credit card regulations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Makes New Investment in InspireMD, Inc. $NSPR

Aberdeen Group plc bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange...

Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 8,411 Shares of Stock

InspireMD, Inc. (NYSE:NSPR - Get Free Report) insider Shane Thomas Gleason sold 8,411 shares of the business's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an...

InspireMD (NYSE:NSPR) Stock Price Down 1.8% - Should You Sell?

InspireMD (NYSE:NSPR) Trading Down 1.8% - Time to Sell...

InspireMD (NYSE:NSPR) Shares Up 2% - Should You Buy?

InspireMD (NYSE:NSPR) Trading 2% Higher - Here's Why...

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of 0.00% and +31.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates

Hologic (HOLX) delivered earnings and revenue surprises of +2.73% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +20.60% and +3.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

Shares of InspireMD, Inc. (NSPR) dipped nearly 1% on Friday morning after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.inspiremd.com/en/press-center/inspiremd-reports-first-quarter-2025-financial-results/">reported</a> a wider-than-expected first quarter (Q1) loss.The company’s revenue for the quarter increased 1.2% year-on-year (YoY) to $1.52 million, above an analyst estimate of $1.45 billion, as per Finchat data.The marginal increase in revenue was driven by the continued adoption of the company’s CGuard technology in existing markets. It was offset by the impact of foreign exchange and distributors managing inventory levels in anticipation of an approval for CGuard Prime in Europe.InspireMD’s CGuard Prime carotid stent system is used to treat carotid artery disease and prevent stroke.Net loss per share came in at $0.22, compared to a net loss of $0.21 per share for the same period in 2024, but wider than an estimated loss of $0.2.The company said that it is continuing to engage with the U.S. Food and Drug Administration (FDA) regarding the application it submitted to obtain marketing approval for the CGuard Prime carotid stent system.The company also expressed optimism about approval for the system in the third quarter of 2025.CEO Marvin Slosman said that the firm’s commercial team is ready to execute at scale upon receiving FDA approval for the technology.“We continue to work interactively with the FDA and are optimistic for an anticipated approval of CGuard Prime in the third quarter of 2025. Despite dynamics within the agency and the timing of our audit in February, we are confident the remaining items will be successfully completed,” he said.On Stocktwits, retail sentiment around InspireMD stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:629/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_11_03_25_AM_png_e35692eebb.webp" alt="NSPR's Sentiment Meter and Message Volume as of 11 a.m. ET on May 9, 2025 | Source: Stocktwits" width="629" height="62"><figcaption>NSPR's Sentiment Meter and Message Volume as of 11 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NSPR">NSPR stock</a> is down by about 3% this year but up by nearly 17% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ocugen-reports-lower-than-expected-q1-loss/chiWHRQRblX">Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa (Photo by Silas Stein/picture alliance via Getty Images)

InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic

The company’s revenue increased marginally to $1.52 million, driven by the continued adoption of its CGuard technology in existing markets.

Equity

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

Current Price	$1.82
Prev Close	$1.81
Open	$1.81
Dividend Yield	0.00%
50-Day Moving Average	$1.78
Beta	0.43
Avg. Volume	35,362.30
PE Ratio	-2.15

52-Week High	$3.80
52-Week Low	$1.51
Market Capitalization	$76.69M
EPS (Annual)	-$0.7633
Price to Book	1.18
Revenue Per Employee	$81,500.00

NSPR
InspireMD Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NSPR News

NSPRInspireMD Inc